AGIO - AGIOS PHARMACEUTICALS, INC.

QQQ $ 439.55 $ 1.32 (0.3 %)

DIA $ 390.50 $ 1.77 (0.46 %)

SPY $ 517.10 $ -0.04 (-0.01 %)

TLT $ 90.18 $ -0.54 (-0.6 %)

GLD $ 213.58 $ -0.63 (-0.29 %)

Previous Close

$ 32.8

Open

$ 32.50

Bid

$ 0.00 x 0

Ask

$ 32.46 x 100

Day's Range

$ 31.87 - $ 32.69

52 Week Range

$ 19.80 - $ 35.50

Volume

704,372

Average Volume

Market Cap

1.85B

Beta (5Y Monthly)

$ 0.93

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-02-2024	03-31-2024	10-Q
2	02-15-2024	12-31-2023	10-K
3	11-02-2023	09-30-2023	10-Q
4	08-03-2023	06-30-2023	10-Q
5	05-04-2023	03-31-2023	10-Q
6	02-23-2023	12-31-2022	10-K
7	11-03-2022	09-30-2022	10-Q
8	08-04-2022	06-30-2022	10-Q
9	05-05-2022	03-31-2022	10-Q
10	02-24-2022	12-31-2021	10-K
11	11-03-2021	09-30-2021	10-Q
12	07-29-2021	06-30-2021	10-Q
13	04-29-2021	03-31-2021	10-Q
14	02-25-2021	12-31-2020	10-K
15	11-05-2020	09-30-2020	10-Q
16	07-30-2020	06-30-2020	10-Q
17	04-30-2020	03-31-2020	10-Q
18	02-19-2020	12-31-2019	10-K
19	10-31-2019	09-30-2019	10-Q
20	08-01-2019	06-30-2019	10-Q
21	05-02-2019	03-31-2019	10-Q
22	02-14-2019	12-31-2018	10-K
23	11-01-2018	09-30-2018	10-Q
24	08-02-2018	06-30-2018	10-Q
25	05-04-2018	03-31-2018	10-Q
26	02-14-2018	12-31-2017	10-K
27	11-01-2017	09-30-2017	10-Q
28	08-08-2017	06-30-2017	10-Q
29	05-04-2017	03-31-2017	10-Q
30	02-16-2017	12-31-2016	10-K
31	11-03-2016	09-30-2016	10-Q
32	08-08-2016	06-30-2016	10-Q
33	05-09-2016	03-31-2016	10-Q
34	02-26-2016	12-31-2015	10-K
35	11-06-2015	09-30-2015	10-Q
36	08-07-2015	06-30-2015	10-Q
37	05-11-2015	03-31-2015	10-Q
38	02-24-2015	12-31-2014	10-K
39	11-07-2014	09-30-2014	10-Q
40	08-07-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Goldman Sachs Maintains Neutral on Agios P...
05/03/2024 15:50:19

Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price targ...

Agios Pharmaceuticals' Cash, Cash Equivale...
05/02/2024 11:06:57

Agios Pharmaceuticals Q1 2024 GAAP EPS $(1...
05/02/2024 11:06:16

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.45) per share which beat the analyst consensus estimate of...

Cantor Fitzgerald Reiterates Overweight on...
04/09/2024 12:27:08

Cantor Fitzgerald analyst Eric Schmidt reiterates Agios Pharmaceuticals (NASDAQ:AGIO) with a Overweight.

RBC Capital Maintains Outperform on Agios ...
02/16/2024 16:58:17

RBC Capital analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Outperform and lowers the price targe...

Agios Pharmaceuticals Q4 Sales $7.10M Miss...
02/15/2024 12:03:22

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly sales of $7.10 million which missed the analyst consensus estimate of $7...

Earnings Scheduled For February 15, 2024
02/15/2024 10:17:01

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on rev...

Earnings Preview: Agios Pharmaceuticals
02/14/2024 17:01:53

Agios Pharmaceuticals Announced Strong Cas...
01/08/2024 12:21:47

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases,...

why-is-blood-disorder-focused-agios-pharmaceuticals-stock-trading-higher-today

Why Is Blood Disorder Focused Agios Pharma...
01/03/2024 14:45:57

Agios Pharmaceuticals Inc (NASDAQ: AGIO) says the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent ...

Market-Moving News for January 3rd
01/03/2024 13:36:09

AGIO: 22% | Agios Pharmaceuticals shares are trading higher after the company announced its Phase 3 ENERGIZE study of Mitapivat...

12-health-care-stocks-moving-in-wednesdays-pre-market-session

12 Health Care Stocks Moving In Wednesday'...
01/03/2024 13:05:55

Agios Announces Phase 3 ENERGIZE Study Of ...
01/03/2024 11:33:59

Agios Presented Results Saturday From Phas...
12/10/2023 12:36:51

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases,...

Agios Announces Clinical Proof-of-Concept ...
11/20/2023 12:04:30

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases,...

Goldman Sachs Maintains Neutral on Agios P...
11/03/2023 14:18:26

Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price targ...

Agios Pharmaceuticals To Present Broad Set...
11/02/2023 13:22:11

– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study i...

Agios Pharmaceuticals' Cash, Cash Equivale...
11/02/2023 11:10:11

Agios Pharmaceuticals Q3 EPS $(1.64) Beats...
11/02/2023 11:08:06

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.64) per share which beat the analyst consensus estimate of...

Earnings Scheduled For November 2, 2023
11/02/2023 08:56:34

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on...